Survival Benefit in Heart Transplant Recipients Who Have Coronary Artery Disease Confirmed Using Angiography and Are Receiving Sirolimus

Transplantation Proceedings

Volumn 41, Issue 1, 2009, Pages 285-288

  Zakliczynski, M ^a   Swierad, M ^a   Nozynski, J ^a   Maruszewski, M ^a   Zembala, M ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CARDIAC GRAFT REJECTION; CASE CONTROL STUDY; CAUSE OF DEATH; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; HEART DEATH; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE;

ADULT; CASE-CONTROL STUDIES; CORONARY ANGIOGRAPHY; CORONARY DISEASE; DEATH; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; SIROLIMUS; SURVIVAL ANALYSIS; SURVIVORS; YOUNG ADULT;

EID: 60649117375     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2008.10.062     Document Type: Article

References (8)

1. Keogh A., Richardson M., Ruygrok P., et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation 110 (2004) 2694
2. Mancini D., Pinney S., Burkhoff D., et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 108 (2003) 48
3. Fukuda D., Sata M., Tanaka K., et al. Potent inhibitory effect of sirolimus on circulating vascular progenitor cells. Circulation 111 (2005) 926
4. Matter C.M., Rozenberg I., Jaschko A., et al. Effects of tacrolimus or sirolimus on proliferation of vascular smooth muscle and endothelial cells. J Cardiovasc Pharmacol 48 (2006) 286
5. Potena L., Holweg C.T., Chin C., et al. Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection. Transplantation 82 (2006) 398
6. Demopoulos L., Polinsky M., Steele G., et al. Reduced risk of cytomegalovirus infection in solid organ transplant recipients treated with sirolimus: a pooled analysis of clinical trials. Transplant Proc 40 (2008) 1407
7. Augustine J.J., Bodziak K.A., and Hricik D.E. Use of sirolimus in solid organ transplantation. Drugs 67 (2007) 369
8. Pham P.T., Pham P.C., and Danovitch G.M. Cardiovascular disease posttransplant. Semin Nephrol 27 (2007) 430